NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
KPIT Technologies Ltd. reported revenue growth of 5.1% QoQ in constant currency terms (our estimate: 4.2%), led by passenger vehicles segment in Europe and Asia.
Operating profit margin stood at 16.7%, up 12 bps QoQ (our estimate: 16.7%), supported by healthy operating efficiency.
For FY2025E, the company has guided for revenue (organic) growth of 18- 22% and expects an Ebitda margin of 20.5%+, post ESOP cost of Rs 1 billion.
We believe KPIT has a strong growth trajectory for coming years given-
its consistent performance,
benign client commentary, and
continued investments for improving moat places.
Ex-of ESOP charges we keep our earnings estimate largely unchanged and retain ‘Accumulate’ rating on discounted cash flow based target price of Rs 1,640 (implies ~two times on PEG basis).
Click on the attachment to read the full report:
Also Read: Mphasis Q4 Results Review - Higher For Longer U.S. Interest Rates Raises Risks: Nirmal Bang
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

GST 2.0 — Auto Sector Gets A Festive Season Booster With Rate Cuts; Maruti Suzuki, M&M Among Top Beneficiaries


Buy, Sell Or Hold: Eternal, CDSL, Suzlon, Natco Pharma, KPIT Tech — Ask Profit


'Hold' Bajaj Auto Shares Says Nirmal Bang, Sees Current Valuations Limits Upside


Tariffs On Auto, Pharma Capped At 15% — US, EU Lock In Trade Deal
